Provided by Tiger Trade Technology Pte. Ltd.

Connect Biopharma Holdings Ltd.

2.43
+0.13005.65%
Post-market: 2.430.00000.00%16:10 EST
Volume:70.89K
Turnover:172.11K
Market Cap:135.85M
PE:-2.74
High:2.57
Open:2.34
Low:2.23
Close:2.30
52wk High:3.28
52wk Low:0.5100
Shares:55.90M
Float Shares:14.34M
Volume Ratio:1.01
T/O Rate:0.49%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8884
EPS(LYR):-0.2830
ROE:-66.80%
ROA:-38.67%
PB:2.45
PE(LYR):-8.59

Loading ...

BTIG Sticks to Its Buy Rating for Connect Biopharma Holdings (CNTB)

TIPRANKS
·
Jan 14

Lake Street Reaffirms Their Buy Rating on Connect Biopharma Holdings (CNTB)

TIPRANKS
·
Jan 13

Connect Biopharma Holdings Ltd - Phase 1B Study Results for Rademikibart Expected in Q1 2026

THOMSON REUTERS
·
Jan 12

Connect Biopharma Announces New Data and Ongoing Trials for Rademikibart in Asthma and COPD

Reuters
·
Jan 12

Connect Biopharma Board Member Kan Chen Resigns

Reuters
·
Dec 24, 2025

Connect Biopharma Initiated at Buy by Lake Street

Dow Jones
·
Dec 02, 2025

Connect Biopharma Holdings to Present at Evercore Healthcare Conference

Reuters
·
Nov 24, 2025

Connect Biopharma Reports Significant Loss Amid Development Efforts

TIPRANKS
·
Nov 18, 2025

Connect Biopharma Price Target Maintained With a $10.00/Share by BTIG

Dow Jones
·
Nov 13, 2025

Connect Biopharma Hldgs Q3 EPS $(0.31) Misses $(0.27) Estimate, Sales $16.000K Down From $1.219M YoY

Benzinga
·
Nov 12, 2025

Connect Biopharma Reports Q3 2025 Results and Advances Rademikibart Clinical Programs

Reuters
·
Nov 12, 2025

Connect Biopharma reports third quarter 2025 financial results

Reuters
·
Nov 12, 2025

Press Release: Connect Biopharma Reports Third Quarter 2025 Financial Results and Provides Business Update

Dow Jones
·
Nov 12, 2025

Connect Biopharma Holdings Ltd : Btig Initiates Coverage With Buy Rating; Price Target $10

THOMSON REUTERS
·
Oct 31, 2025

Connect Biopharma Initiated at Buy by BTIG

Dow Jones
·
Oct 31, 2025

Connect Biopharma initiated with a Buy at BTIG

TIPRANKS
·
Oct 31, 2025

Buy Rating for Connect Biopharma: Promising Clinical Data and Market Potential for Rademikibart

TIPRANKS
·
Sep 29, 2025

Connect Biopharma presents data on rademikibart at ERS Congress

TIPRANKS
·
Sep 29, 2025

Connect Biopharma Announces Promising Phase 2 Data for Rademikibart in Asthma and COPD, with Topline Results Expected in 1H 2026

Reuters
·
Sep 29, 2025

Connect Biopharma Executives Increase Share Holdings

TIPRANKS
·
Sep 16, 2025